Pharmacokinetics of rosiglitazone in patients with end-stage renal disease

J Int Med Res. Jul-Aug 2002;30(4):391-9. doi: 10.1177/147323000203000405.

Abstract

The pharmacokinetics and tolerability of a single 8-mg oral dose of rosiglitazone, an anti-diabetic agent, were compared in 10 long-term haemodialysis patients and 10 healthy volunteers. Haemodialysis patients received rosiglitazone 4 h after haemodialysis (non-dialysis day) and 3 h before haemodialysis (dialysis day). Haemodialysis did not influence rosiglitazone pharmacokinetics, and dialytic clearance was low (0.10 1/h). The mean area under the concentration-time curve (AUC(0-infinity)), the maximum observed plasma concentration (Cmax) and the half-life for rosiglitazone were similar in haemodialysis patients (non-dialysis day) and healthy individuals (2192 +/- 598 ng.h/ml versus 2388 +/- 494 ng.h/ml, 338 +/- 114 ng/ml versus 373 +/- 95 ng/ml, and 3.70 +/- 0.75 h versus 3.81 +/- 0.86 h, respectively). AUC(0-infinity) and Cmax were not markedly influenced by haemodialysis. Rosiglitazone dose adjustments are not warranted in patients with type 2 diabetes with end-stage renal failure on haemodialysis.

Publication types

  • Clinical Trial
  • Comparative Study

MeSH terms

  • Adult
  • Aged
  • Female
  • Humans
  • Hypoglycemic Agents / blood
  • Hypoglycemic Agents / pharmacokinetics*
  • Hypoglycemic Agents / therapeutic use
  • Kidney Failure, Chronic / metabolism*
  • Male
  • Middle Aged
  • Renal Dialysis
  • Rosiglitazone
  • Thiazoles / blood
  • Thiazoles / pharmacokinetics*
  • Thiazoles / therapeutic use
  • Thiazolidinediones*

Substances

  • Hypoglycemic Agents
  • Thiazoles
  • Thiazolidinediones
  • Rosiglitazone